U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
November-18-2011
Last Update:
Dec-15-2024
FDA-Approved Indications
EYLEA (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
Neovascular (Wet) Age-Related Macular Degeneration (AMD);
Macular Edema Following Retinal Vein Occlusion (RVO);
Diabetic Macular Edema (DME);
Diabetic Retinopathy (DR);
Retinopathy of Prematurity (ROP).
aBLA / 505(b)(2) Activity
aBLA / 505(b)(2) Approved by FDA
Yesafili: Biocon (Mylan) / Momenta (May-2024, Interchangeable) Opuviz: Samsung Bioepis (May-2024, Interchangeable) Ahzantive® (Formycon / Klinge Biopharma) (June-2024) Enzeevu (Sandoz) (August-2024, Provisionally Interchangeable) Pavblu: Amgen (August-2024)
aBLA / 505(b)(2) Accepted by FDA
CT-P42: Celltrion (June-2023)
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Afqlir® (Sandoz) (November-2024) Opuviz (Samsung Bioepis / Biogen) (November-2024)Yesafili (Biocon) (September-2023 in the EU; November-2023 in the UK)
Biosimilars Approved In South Korea
Afilivu (Samsung Bioepis / Samil) (February-2024) Eydenzelt (Celltrion) (May-2024)
Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted; Request for Rehearing Withdrawn
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Terminated Prior to Institution Decision at Petitioner's Request)
IPR Status
Terminated Prior to Institution Decision at Petitioner's Request
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
No Decision
IPR Status
Administratively Closed, No Decision
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Chengdu Kanghong Biotechnology Co., Ltd.; Bejing Kanghong Biomedical Co. Ltd.; Chengdu Kanghong Pharmaceutical Group Co. Ltd.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Terminated Prior to Institution Decision
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
IPR Status
Terminated Prior to Institution Decision (Petitioner Requested Dismissal)
U.S. Patent No.
9,220,631 (Syringe)
Patent Owner
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Petitioner(s)
Regeneron Pharmaceuticals, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-26
Claim Types Challenged Under § 103
Method of Treatment Other
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1334
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Joined with IPR2021-00880; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Joined with IPR2021-00881; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1396 (consolidated with lead appeal 23-1395)
IPR Status
Joined with IPR2021-00881; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 8-12
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
23-1395
IPR Status
Joined with IPR2021-00880; Final Written Decision (All Challenged Claims Unpatentable); Fed. Cir. Appeal Voluntarily Dismissed
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
24-1564 (lead appeal, conslidated with 24-1567)
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
24-1567 (consolidated with lead appeal 24-1564)
IPR Status
Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Apotex Inc.; Apotex Corp.; Apotex Pharmaceutical Holdings Inc.; Aposhem Delaware Holdings Corporation
§ 102 Challenge
Y: Claims 1-5, 8-11, 14, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N
§ 103 challenge
Y: Claims 6, 7, 12, 13
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
IPR Status
IPR Not Instituted
U.S. Patent No.
10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Mylan Pharmaceuticals Inc.; Mylan Inc.; Viatris Inc.; Momenta Pharmaceuticals, Inc.; Johnson & Johnson; Janssen Research & Development LLC
§ 102 Challenge
Y: Claims 1-3
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N
§ 103 challenge
Y: Claims 1-3
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)
IPR Status
IPR Not Instituted Due to Disclaimer
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
IPR Status
Final Written Decision (All Challenged Claims Unpatentable)
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Y
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims After Institution Decision)
IPR Status
Adverse Judgment After Disclaimer
U.S. Patent No.
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1, 3-11, 13-14, 16-24, 26
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
y
Federal Circuit Appeal(s)
24-1564 (lead appeal, conslidated with 24-1567)
IPR Status
Joined with IPR2022-01225; Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
y
Federal Circuit Appeal(s)
24-1567 (consolidated with lead appeal 24-1564)
IPR Status
Joined with IPR2022-01226; Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-9, 34-39, 41-43, 45
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
24-1567 (consolidated with lead appeal 24-1564)
IPR Status
Joined with IPR2022-01226; Final Written Decision (All Challenged Claims Unpatentable); Federal Circuit Appeal Voluntarily Dismissed
U.S. Patent No.
10,406,226 (Method of Manufacturing VEGF Antagonist Fusion Proteins)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-4
Claim Types Challenged Under § 103
Manufacturing
§ 103 Challenge Instituted
N
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims Prior to Institution Decision)
IPR Status
Institution Denied Due to Disclaimer of All Challenged Claims
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 13-16, 20, 22-24, 29-32, 46-47
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
N (Claims Disclaimed)
§ 103 challenge
Y: Claims 10-33
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y: Claims 10-12, 17-19, 21, 25-28, 33 (Other Claims Disclaimed)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Disclaimed In Part- Claims 13-14, 22, 29-30 Disclaimed Prior to Petition Filing; Claims 15-16, 20
IPR Status
Claims 13-14, 22, 29-30 Disclaimed Prior to Petition Filing; Claims 15-16, 20, 23-24, 31-32, 46-47 Disclaimed Prior to Institution Decision; Adverse Judgment After Institution Due to Disclaimer of Claims 10-12, 17-19, 21, 25-28, 33
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-5, 8-11, 15-17, 20-21, 24, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-14, 16-23, 25-30
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Adverse Judgment Due to Disclaimer)
IPR Status
Adverse Judgment After Institution Due to Disclaimer
U.S. Patent No.
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
Y: Claims 1-18
Claim Types Challenged Under § 102
Formulation
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-18
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Y (Joined)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Patent Owner Disclaimed All Challenged Claims After Institution Decision)
IPR Status
Joined with IPR2023-00462; Adverse Judgment After Disclaimer
U.S. Patent No.
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Biocon Biologics Inc.; Biocon Biologics Limited; Biocon Biologics UK Limited; Biocon Limited; Biosimilar Collaborations Ireland Limited; Janssen Research & Development, LLC; Johnson & Johnson; Momenta Pharmaceuticals, Inc.; Mylan Inc.; Mylan Pharmaceuticals Inc.; Viatris Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 10-12, 17-19, 21, 25-28, 33
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Adverse Judgment Due to Disclaimer)
IPR Status
Joined with IPR2023-00739; Adverse Judgment After Institution Due to Disclaimer
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.
§ 102 Challenge
Y: Claims 1-5, 8-11, 15-17, 20-21, 24, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-14, 16-23, 25-30
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Adverse Judgment Due to Disclaimer)
IPR Status
Joined with IPR2023-00884; Adverse Judgment After Institution Due to Disclaimer
U.S. Patent No.
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Biocon Biologics Inc.; Biocon Biologics Limited; Biocon Biologics UK Limited; Biocon Limited; Biosimilar Collaborations Ireland Limited; Janssen Research & Development, LLC; Johnson & Johnson; Momenta Pharmaceuticals, Inc.; Mylan Inc.; Mylan Pharmaceuticals Inc.; Viatris Inc.
§ 102 Challenge
Y: Claims 1-5, 8-11, 15-17, 20-21, 24, 26-30
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Y (Joined)
§ 103 challenge
Y: Claims 1-14, 16-23, 25-30
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y (Joined)
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Adverse Judgment Due to Disclaimer)
IPR Status
Joined with IPR2023-00884; Adverse Judgment After Institution Due to Disclaimer
U.S. Patent No.
11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Samsung Bioepis Co., Ltd.
§ 102 Challenge
N
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-12, 14-17, 19-20, 22-36, 39-42, 44-45, 47-55
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Awaiting Institution Decision
IPR Status
Awaiting Institution Decision
U.S. Patent No.
11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Formycon AG
§ 102 Challenge
N
§ 102 Challenge Instituted
Y
§ 103 challenge
Y: Claims 1-12, 14-17, 19-20, 22-36, 39-42, 44-45, 47-55
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
Awaiting Institution Decision; Motion for Joinder
IPR Status
Awaiting Institution Decision; Motion for Joinder with IPR2025-00176
U.S. Patent No.
10,828,345 (Use of a VEGF Antagonsit to Treat Angiogenic Eye Disorders)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Chengdu Kanghong Biotechnology Co., Ltd.; Bejing Kanghong Biomedical Co. Ltd.; Chengdu Kanghong Pharmaceutical Group Co. Ltd.
§ 102 Challenge
Y: Claims 1-11
Claim Types Challenged Under § 102
Method of Treatment
§ 102 Challenge Instituted
Terminated Prior to Institution Decision
§ 103 challenge
Y: Claims 1-11
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Terminated Prior to Institution Decision
Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Dismissal)
IPR Status
Terminated Prior to Institution Decision (Petitioner Requested Dismissal)
U.S. Patent No.
10,857,231 (Formulations of VEG Antagonist Fusion Proteins and Method of Manufacturing Them)
Patent Owner
Regeneron Pharmaceuticals, Inc.
Petitioner(s)
Celltrion, Inc.; Celltrion Healthcare Co., Ltd.; Celltrion Healthcare USA, Inc.
§ 102 Challenge
N
§ 103 challenge
Y: Claims 1-4, 6-11, 18-21, 27-32, 41-45, 58-59
Claim Types Challenged Under § 103
Formulation
§ 103 Challenge Instituted
N
IPR Status
Challenges Include Written Description (Claims 1-11, 17-21, 27-32, 41-53, 58-67), Enablement (Claims 1-11, 17-21, 27-32, 41-53, 58-67), and Indefiniteness (Claims 1-11, 17-21, 27-32, 41-53, 58-67); Institution Denied
U.S. Patent Litigations
PACER
Case No(s):
U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)
Plaintiffs
Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Grifols Worldwide Operations Limited
Defendants
Regeneron Pharmaceuticals, Inc.
Status
Stipulated Judgment of Non-Infringement and Order of Dismissal
BPCIA
N
U.S. Patent Nos.
9,220,631 (Syringe)
Plaintiffs
Novartis Pharma AG; Novartis Pharmaceuticals Corporation; Novartis Technology LLC
Defendants
Regeneron Pharmaceuticals, Inc.
Status
Stipulated Dismissal After Claims Found Unpatentable in IPR2021-00816
BPCIA
N
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,669,069 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,406,226 (Method of Manufacturing VEGF Antagonist Fusion Proteins) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,857,205 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 10,973,879 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,186,625 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,332,771 (Serum-Free Cell Culture Medium)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Mylan Pharmaceuticals Inc.; Biocon Biologics Inc.; Amgen USA, Inc. (Intervenor)
Federal Circuit Appeal(s)
24-1402 (lead); 24-1405 (cross); 24-2002 (Permanent Injunction)
Status
Judgment: Claims 4, 7, 9, 11, 14-17 of U.S. Patent No. 11,084,865 valid and infringed; Claims 6 and 25 of U.S. Patent No. 11,253,572 and Claims 11 and 19 of U.S. Patent No. 10,888,601 invalid and infringed; Federal Circuit Appeals Dismissed Due to Lack of Jurisdiction. Summary Judgment of Noninfringement Due to Disclaimer: 10,406,226, 10,464,992, and 10,857,205 Patents; Permanent Injunction Issued, Federal Circuit Appeal Ongoing
BPCIA
Y
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,332,771 (Serum-Free Cell Culture Medium) 11,459,374 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,485,770 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,505,593 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,525,833 (Hydrophobic Interaction Chromatography-Coupled Native Mass Spectrometry for Antibody Analysis) 11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,555,176 (Cell Culture Medium for Eukaryotic Cells) 11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF) 11,788,102 (CHO Integration Sites and Uses Thereof) 11,793,926 (Medical Device Packaging and Related Methods)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Celltrion, Inc.
Federal Circuit Appeal(s)
Preliminary Injunction: 24-2058 (lead), 24-2147 (consolidated)
Status
Case Ongoing, Preliminary Injunction Granted, Federal Circuit Appeals Ongoing
BPCIA
Y
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials) 9,562,238 (Enhanced Expression and Stability Regions) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,905,786 (Sterilisation Method) 10,918,754 (Sterilisation Method) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,332,771 (Serum-Free Cell Culture Medium) 11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,485,770 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,555,176 (Cell Culture Medium for Eukaryotic Cells) 11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF) 11,788,102 (CHO Integration Sites and Uses Thereof)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Samsung Bioepis Co., Ltd.
Federal Circuit Appeal(s)
Preliminary Injunction: 24-1966, 24-2083 (both consolidated with 24-1965 lead)
Status
Case Ongoing, Preliminary Injunction Granted, Federal Circuit Appeals Ongoing
BPCIA
Y
U.S. Patent Nos.
7,070,959 (Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties) 7,771,997 (Enhanced Expression and Stability Regions) 9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,562,238 (Enhanced Expression and Stability Regions) 9,816,110 (CHO Integration Sites and Uses Thereof) 9,932,605 (Enhanced Expression and Stability Regions) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,415,055 (Enhanced Expression and Stability Regions) 10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,268,109 (CHO Integration Sites and Uses Thereof) 11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,332,771 (Serum-Free Cell Culture Medium) 11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,485,770 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants) 11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,549,154 (Compositions and Methods for Detecting a Biological Contaminant) 11,555,176 (Cell Culture Medium for Eukaryotic Cells) 11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,680,930 (Methods and Systems for Chromatography Data Analysis) 11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF) 11,788,102 (CHO Integration Sites and Uses Thereof)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Formycon AG
Federal Circuit Appeal(s)
Preliminary Injunction: 24-2009 (lead), 24-2019 (consolidated), 24-2156 (consolidated)
Status
Case Ongoing, Preliminary Injunction Granted, Federal Circuit Appeals Ongoing
BPCIA
Y
U.S. Patent Nos.
9,222,106 (Enhanced Expression and Stability Regions)
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials)
9,562,238 (Enhanced Expression and Stability Regions)
9,816,110 (CHO Integration Sites and Uses Thereof)
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,182,969 (Aseptic Piercing System and Method)
10,415,055 (Enhanced Expression and Stability Regions)
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
10,669,594 (Compositions and Methods for Detecting a Biological Contaminant)
10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,905,786 (Sterilisation Method)
10,918,754 (Sterilisation Method)
10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use)
11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,103,552 (High Concentration VEGF Receptor Fusion Protein Containing Formulations)
11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,160,918 (Medical Device Packaging and Related Methods)
11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use)
11,332,771 (Serum-Free Cell Culture Medium)
11,433,186 (Devices and Methods for Precision Dose Delivery)
11,439,758 (Devices and Methods for Precision Dose Delivery)
11,459,374 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,478,588 (Needle Shield Grip Devices and Related Methods)
11,485,770 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,505,593 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,555,176 (Cell Culture Medium for Eukaryotic Cells)
11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,577,025 (Devices and Methods for Overfilling Drug Containers)
11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF)
11,788,102 (CHO Integration Sites and Uses Thereof)
11,793,926 (Medical Device Packaging and Related Methods)
D858,754 (Syringe Cap)
D906,102 (Packaging)
D934,069 (Packaging)
D961,376 (Packaging)
D961,377 (Packaging)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Samsung Bioepis Co., Ltd.
Federal Circuit Appeal(s)
Preliminary Injunction: 24-1965 (lead); 24-2082 (consolidated)
Status
Case Ongoing, Preliminary Injunction Granted, Federal Circuit Appeals Ongoing
BPCIA
Y
U.S. Patent Nos.
9,222,106 (Enhanced Expression and Stability Regions)
9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials)
9,816,110 (CHO Integration Sites and Uses Thereof)
10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,415,055 (Enhanced Expression and Stability Regions)
10,464,992 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
10,669,594 (Compositions and Methods for Detecting a Biological Contaminant)
10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,905,786 (Sterilisation Method)
10,918,754 (Sterilisation Method)
11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,160,918 (Medical Device Packaging and Related Methods)
11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,306,135 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,505,593 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,542,317 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,555,176 (Cell Culture Medium for Eukaryotic Cells)
11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,680,930 (Methods and Systems for Chromatography Data Analysis)
11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF)
11,788,102 (CHO Integration Sites and Uses Thereof)
11,793,926 (Medical Device Packaging and Related Methods)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Amgen, Inc.
Supreme Court Appeal(s)
24-2351
Status
Case Ongoing; Preliminary Injunction Denied, Federal Circuit Appeal (Preliminary Injunction) Pending, Temporary Injunction Pending Appeal Denied
BPCIA
Y
U.S. Patent Nos.
9,222,106 (Enhanced Expression and Stability Regions) 9,254,338 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials) 9,816,110 (CHO Integration Sites and Uses Thereof) 10,130,681 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,415,055 (Enhanced Expression and Stability Regions) 10,669,594 (Compositions and Methods for Detecting a Biological Contaminant) 10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,888,601 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,253,572 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use) 11,332,771 (Serum-Free Cell Culture Medium) 11,505,593 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,525,833 (Hydrophobic Interaction Chromatography-Coupled Native Mass Spectrometry for Antibody Analysis) 11,555,176 (Cell Culture Medium for Eukaryotic Cells) 11,559,564 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,707,506 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders) 11,732,024 (VEGF Antagonist Formulations Suitable for Intravitreal Administration) 11,753,459 (Anti-VEGF Protein Compositions and Methods for Producing the Same) 11,769,597 (Methods of Associating Genetic Variants with a Clinical Outcome in Patients Suffering from Age-Related Macular Degeneration Treated with Anti-VEGF) 11,788,102 (CHO Integration Sites and Uses Thereof) 11,793,926 (Medical Device Packaging and Related Methods)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Celltrion, Inc.
Status
Case Ongoing
BPCIA
Y
U.S. Patent Nos.
9,222,106 (Enhanced Expression and Stability Regions)
9,315,281 (System and Methods for Use in Dispensing Biopharmaceutical Materials)
9,816,110 (CHO Integration Sites and Uses Thereof)
10,182,969 (Aseptic Piercing System and Method)
10,415,055 (Enhanced Expression and Stability Regions)
10,669,594 (Compositions and Methods for Detecting a Biological Contaminant)
10,828,345 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
10,905,786 (Sterilisation Method)
10,918,754 (Sterilisation Method)
10,927,342 (Taurine Supplemented Cell Culture Medium and Methods of Use)
11,053,280 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,066,458 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,084,865 (VEGF Antagonist Formulations Suitable for Intravitreal Administration)
11,104,715 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,160,918 (Medical Device Packaging and Related Methods)
11,174,283 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,268,109 (CHO Integration Sites and Uses Thereof)
11,299,532 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,312,936 (Taurine Supplemented Cell Culture Medium and Methods of Use)
11,332,771 (Serum-Free Cell Culture Medium)
11,406,565 (Aseptic Piercing System and Method)
11,433,186 (Devices and Methods for Precision Dose Delivery)
11,439,758 (Devices and Methods for Precision Dose Delivery)
11,459,373 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,459,374 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,472,861 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,478,588 (Needle Shield Grip Devices and Related Methods)
11,535,663 (Methods for Producing Aflibercept in Chemically Defined Media Having Reduced Aflibercept Variants)
11,548,932 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,555,176 (Cell Culture Medium for Eukaryotic Cells)
11,577,025 (Devices and Methods for Overfilling Drug Containers)
11,732,025 (Anti-VEGF Protein Compositions and Methods for Producing the Same)
11,788,102 (CHO Integration Sites and Uses Thereof)
11,793,926 (Medical Device Packaging and Related Methods)
11,850,407 (Needle Shield Grip Devices and Related Methods)
11,918,785 (Devices and Methods for Overfilling Drug Containers)
11,970,724 (Serum-free Cell Culture Medium)
11,975,045 (Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders)
D858,754 (Syringe Cap)
D906,102 (Packaging)
D934,069 (Packaging)
D961,376 (Packaging)
D961,377 (Packaging)
D1,024,321 (Retainer Adapter Assembly)
D1,028,224 (Retainer Adapter Assembly)
D1,035,436 (Packaging)
Plaintiffs
Regeneron Pharmaceuticals, Inc.
Defendants
Sandoz Inc.
Status
Case Ongoing
BPCIA
Y
